BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more accessible and affordable to cancer patients worldwide. We have a commercial presence in more than 60 markets, with products treating various forms of cancer, and our broad and deep pipeline has the potential to address 80 percent of cancers by incidence.
We have grown rapidly since our founding in 2010 to more than 9,000 colleagues working on five continents, including more than 950 oncology researchers, one of the largest such teams in the industry. We have administrative offices in Basel, Beijing and Cambridge, U.S.
As we have grown, we have also evolved. In 2022, the company published its first Environmental, Social and Governance report and introduced “Change in the Cure,” a framework that provides a path for helping us shape a better world by advancing global health, improving access to medicines and ensuring quality in all our work. We have also introduced initiatives to improve work/life balance for our colleagues. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal. See our community guidelines: bit.ly/39o3O6j
|
|
|
1,001-5,000 employees
View all BeiGene employees
|
|
Biotechnology
|
|
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
|
|
2010
|
|
Targeted Therapy And Immuno-Oncology
|
John Oyler is the CEO of BeiGene. To contact John Oyler email at [email protected], [email protected] or [email protected].
The decision makers in BeiGene are Alex Shihmin Huang, Ed Fitzgerald, Hong Tian, etc. Click to Find BeiGene decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.